Illinois Municipal Retirement Fund lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 15.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,385 shares of the medical research company’s stock after selling 776 shares during the period. Illinois Municipal Retirement Fund’s holdings in Thermo Fisher Scientific were worth $2,960,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also added to or reduced their stakes in TMO. BlackRock Inc. bought a new position in Thermo Fisher Scientific during the second quarter worth $15,501,867,000. Corient Private Wealth LP acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $382,547,000. Bank of New York Mellon Corp bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $1,974,561,000. Bank of America Corp DE bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $1,952,930,000. Finally, Legal & General Group Plc acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $1,122,351,000. Institutional investors and hedge funds own 89.23% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have weighed in on TMO. Evercore lowered their price target on shares of Thermo Fisher Scientific from $720.00 to $615.00 and set an “outperform” rating on the stock in a report on Wednesday, October 28th. Robert W. Baird upped their target price on Thermo Fisher Scientific from $723.00 to $756.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. Citigroup lifted their price target on Thermo Fisher Scientific from $685.00 to $800.00 and gave the stock a “buy” rating in a report on Friday, October 23rd. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Finally, Royal Bank Of Canada upped their price objective on Thermo Fisher Scientific from $580.00 to $730.00 and gave the company a “sector perform” rating in a report on Thursday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $683.64.
Read Our Latest Research Report on Thermo Fisher Scientific
Thermo Fisher Scientific Stock Performance
Thermo Fisher Scientific stock traded up $0.54 during midday trading on Friday, hitting $699.98. The company’s stock had a trading volume of 1,837,337 shares, compared to its average volume of 2,259,394. The company has a 50-day moving average price of $670.82 and a two-hundred day moving average price of $556.81. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $727.56. The company has a market cap of $259.36 billion, a price-to-earnings ratio of 36.92, a PEG ratio of 2.85 and a beta of 0.84. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.81 and a quick ratio of 1.41.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, topping the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The company had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. During the same period last year, the firm earned $5.79 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.27 earnings per share for the current year.
Thermo Fisher Scientific Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 15th. Shareholders of record on Tuesday, December 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.92%.
Insiders Place Their Bets
In other Thermo Fisher Scientific news, VP Lisa Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at $9,064,366.08. The trade was a 43.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $77,982,284.75. This represents a 7.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 24,546 shares of company stock worth $15,479,192. Corporate insiders own 0.33% of the company’s stock.
Key Stories Impacting Thermo Fisher Scientific
These are some of the TMO stories that stood out recently:
- Positive Sentiment: Industry reports forecast substantial growth in markets where Thermo Fisher competes, including single-use bioprocessing, cell lysis and fractionation, and cell-culture coatings. These projections point to potential demand tailwinds, but are third-party market estimates, not company-specific forecasts. Article: Single-use bioprocessing market report Article: Cell lysis and fractionation market report Article: Cell culture protein surface coating market report
- Neutral Sentiment: CEO Marc Casper is scheduled to join a UBS fireside chat on November 19. Investors may listen for business commentary, but the announcement itself contains no new financial or operational information. Article: UBS CEO Call Series
- Neutral Sentiment: A recent analysis revisits Thermo Fisher’s $5 billion buyback and cash generation after strong multiyear share gains. The buyback supports capital returns, while the discussion highlights the need for future cash flows to justify expectations; the article excerpt gives no new buyback details or firm valuation conclusion. Article: Is Thermo Fisher reasonable after its $5 billion buyback?
Thermo Fisher Scientific Profile
Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
